Compare Enovix Corporation (ENVX) vs Hims and Hers Health Inc (HIMS) Price & Performance

ENVX is trading at $4.59, down 9.29% in the last session, with a bearish technical signal. The company shows consistent quarterly earnings beats but remains deeply unprofitable with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in commercial battery production for smart eyewear and smartphone markets.

Despite analyst optimism (75% buy ratings, $12.75 consensus target), ENVX faces significant execution risks as it scales production. The stock offers speculative growth potential in advanced battery technology but requires substantial revenue acceleration to justify current valuations amid persistent cash burn and negative profitability.

Hims & Hers Health trades at $34.78, down 1.05% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $2.35B revenue in 2025 but faces profitability challenges with a negative net income margin of -0.56% and elevated valuation ratios including a P/E of 57.14. Recent news highlights expansion in weight-loss therapies and international markets, with Q2 2026 earnings due August 10, 2026.

The outlook remains cautiously optimistic with analyst consensus at Buy (35%) and a $33.57 price target near current levels. Key opportunities include GLP-1 therapy growth and subscriber additions, while risks involve profitability pressures, competitive threats, and reliance on regulatory approvals. The stock's performance hinges on execution in high-margin segments and cost management amid expansion.